Bone scintigraphy screening in stage I-II breast cancer: is it cost-effective?
Where this comes from
- Record sourced from PubMed, PMID 8590515.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It is recommended that routine bone scans not be adopted for follow-up of patients with stage I-II breast cancer. Bone scintigraphy should be reserved for evaluation of patients presenting with symptoms suggestive of bone metastases.